drugset / Trial / NCT02149225
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Phase 1
Completed
16 enrolled
Immatics Biotechnologies GmbH
BCN Peptides · collabBioNTech SE · collabEU-funded GAPVAC Consortium · collabUniversity Hospital Tuebingen · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety and tolerability, feasibility and biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept in newly diagnosed glioblastoma (GB) patients.
Timeline
- Start
- 2014-10
- Primary completion
- 2018-06
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APVAC1 vaccine | Vaccine | 578 ug | Intravitreal |
| Subject | APVAC2 vaccine | Vaccine | 578 ug | Intravitreal |
| Background | Hiltonol | Other / unclassified | 1.5 mg | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | 75 ug | Intravitreal |